Enovis Corp (ENOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enovis Corp (ENOV) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($88.54 Million) by net assets ($1.49 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enovis Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Enovis Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Enovis Corp for a breakdown of total debt and financial obligations.
Enovis Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enovis Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Happy Forgings Limited
NSE:HAPPYFORGE
|
0.018x |
|
Kelt Exploration Ltd.
TO:KEL
|
0.048x |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
N/A |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
0.022x |
|
Home First Finance Company India Limited
NSE:HOMEFIRST
|
-0.121x |
|
Shanghai Chengdi Constr Co
SHG:603887
|
0.201x |
|
One Software Technologies Ltd
TA:ONE
|
0.094x |
|
Chongqing Department Store Co Ltd
SHG:600729
|
0.066x |
Annual Cash Flow Conversion Efficiency for Enovis Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Enovis Corp from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Enovis Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.49 Billion | $217.29 Million | 0.146x | +229.05% |
| 2024-12-31 | $2.56 Billion | $113.50 Million | 0.044x | +12.17% |
| 2023-12-31 | $3.42 Billion | $134.99 Million | 0.039x | +343.71% |
| 2022-12-31 | $3.45 Billion | $-55.86 Million | -0.016x | -121.20% |
| 2021-12-31 | $4.66 Billion | $356.10 Million | 0.076x | -9.22% |
| 2020-12-31 | $3.59 Billion | $301.94 Million | 0.084x | +124.26% |
| 2019-12-31 | $3.49 Billion | $130.95 Million | 0.038x | -42.36% |
| 2018-12-31 | $3.48 Billion | $226.37 Million | 0.065x | +10.92% |
| 2017-12-31 | $3.73 Billion | $218.77 Million | 0.059x | -26.49% |
| 2016-12-31 | $3.09 Billion | $246.97 Million | 0.080x | -14.42% |
| 2015-12-31 | $3.26 Billion | $303.81 Million | 0.093x | -18.92% |
| 2014-12-31 | $3.35 Billion | $385.76 Million | 0.115x | -12.91% |
| 2013-12-31 | $2.74 Billion | $362.17 Million | 0.132x | +73.40% |
| 2012-12-31 | $2.16 Billion | $164.30 Million | 0.076x | -74.77% |
| 2011-12-31 | $189.28 Million | $57.15 Million | 0.302x | +5.44% |
| 2010-12-31 | $216.37 Million | $61.97 Million | 0.286x | +48.73% |
| 2009-12-31 | $198.83 Million | $38.29 Million | 0.193x | +202.00% |
| 2008-12-31 | $166.93 Million | $-31.51 Million | -0.189x | -113.45% |
| 2007-12-31 | $53.05 Million | $74.48 Million | 1.404x | +147.72% |
| 2006-12-31 | $5.90 Million | $-17.36 Million | -2.942x | -387.56% |
| 2005-12-31 | $-7.58 Million | $-7.75 Million | 1.023x | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more